Five lessons from biopharma companies’ data transformation journeys
Author: Sebastian Wurst, Director, OpenData Strategy, Europe As global biopharmas expand into new markets, they introduce more systems to handle increasing …
Post
-
-
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access …
-
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder …
-
Big pharma braces for revenue headwinds as patent expiries loom
One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for …
-
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU). This approval from the European …
-
Brii Biosciences and Joincare sign licence agreement for BRII-693
Brii Biosciences and the Joincare Pharmaceutical Group have signed a licence and technology transfer agreement for BRII-693, a new synthetic …
-
Theratechnologies shares surge 25% amid $254m Future Pak takeover
Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of …
-
UK Government reveals 10-year plan for NHS
The UK’s Labour Government has revealed its ’10-Year Health Plan’ for the country’s National Health Service (NHS). Speaking at a community …
-
BioVersys and Shionogi agree to develop ansamycin leads
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from …
-
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
Regeneron has won US Food and Drug Administration (FDA) approval for Lynozyfic (linvoseltamab-gcpt), marking the entry of another BCMAxCD3 bispecific …
-
Ligand’s LNHC concludes merger with CHRO
Ligand Pharmaceuticals’ wholly owned subsidiary LNHC has concluded its merger with Channel Therapeutics’ CHRO Merger Sub, resulting in the formation …
-
Navigating the AI regulatory maze: Why 91% of life sciences professionals feel lost
Only 9% of life sciences professionals understand U.S. and EU artificial intelligence (AI) regulations well.[1] Let that sink in. While your executive …
-
Podcast: The importance of Social Determinants of Health (SDoH)
As the focus on personalized, equitable healthcare continues to intensify, social determinants of health (SDoH) have attracted significant attention in …
-
FDA approves Dizal’s Zegfrovy to treat adults with NSCLC
Dizal has received US Food and Drug Administration (FDA) approval for Zegfrovy (sunvozertinib) to treat adults with locally advanced or …
-
Protecting patients’ data is vital for NHS single health record system
Experts are emphasising that safeguarding patient data from corporations and cyberattacks is vital for the NHS to create a single …
